Does anti‐HPA‐1a affect birthweight in fetal and neonatal alloimmune thrombocytopenia?

Abstract

AbstractBackgroundFetal and neonatal alloimmune thrombocytopenia (FNAIT) ensues from parental incompatibility for platelet alloantigens with maternal sensitization. HPA‐1a/1b incompatibility is the most common cause of FNAIT in Caucasians. Placental villitis and lower birthweight in FNAIT suggest anti‐HPA‐1a may have effects beyond inducing thrombocytopenia.ObjectivesDoes FNAIT secondary to anti‐HPA‐1a result in smaller newborns and, the corollary, does antenatal management of FNAIT increase birthweight?Study designBirthweights of 270 FNAIT‐affected newborns from a randomized clinical trial and a NAITbabies.org survey (135 paired siblings) were compared with those of published controls and treated to untreated FNAIT‐affected siblings. Birthweights were converted to percentiles to account for gestational age, sex, and role of birth order in birth weight. Body weights of FNAIT‐affected and ‐unaffected pups in a mouse FNAIT model were analyzed.ResultsUntreated siblings in both the clinical trial and NAITbabies.org cohorts were not small, compared with normal controls. However, treated siblings in both cohorts had significantly higher birthweight percentiles compared with their previous untreated affected sibling. After accounting for gestational age, sex, and birth order, increased birthweight percentile in treated compared with the untreated siblings remained significant in both cohorts. FNAIT‐affected neonatal mice had lower bodyweights than FNAIT‐unaffected pups.ConclusionsUntreated FNAIT‐affected newborns were not small; however, treatment of FNAIT‐affected pregnancies increased newborn birthweights despite corrections to account for other factors that might have influenced the results. High dose IVIG is believed to “block” FcRn and lower maternal anti‐HPA‐1a levels, and thus increase birthweights by reducing levels of maternal anti‐HPA‐1a and reducing placental villitis.